New study Fine-Tunes malaria drug dosing for kids
NCT ID NCT05750459
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at how the malaria drug artesunate works in 90 Ugandan children aged 6 months to 14 years with severe malaria. Researchers measured drug levels in the blood and tracked vital signs like temperature and blood pressure to see how the body responds. The goal was to better understand the right dose for children to improve treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- artesunate
- What this could lead to
- If successful, this study could help doctors give the right dose of IV artesunate to children with severe malaria, potentially improving recovery.
- What could go wrong
- This is a small, single-site study that measured drug levels and body responses, not whether the drug works better than other treatments. Results may not apply to all children.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMODIUM FALCIPARUM INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Makerere University-Infectious Diseases Institute
Kampala, Uganda
More trials for these conditions
Other studies related to the condition(s) this trial covers.